Cancer can lead to . What else might add to your risk?
Active Therapy for Cancer
Cancer therapy itself has been shown to increase the risk for , including , anti-angiogenic therapy, hormonal therapy, and erythropoietin-stimulating agents1. The underlying mechanisms are poorly understood, but it has been suggested that many of these therapeutic agents induce vascular damage2.
is also a common complication of cancer-related surgery. The frequency of in patients undergoing cancer surgery is roughly twice that seen in patients without malignancies who have similar operations3.
Hospitalisation is often associated with prolonged immobility (due to bedrest or recovery). This is a strong risk factor for cancer-associated . In the hospitalised setting, the rate of in cancer patients is twice that of non-cancer patients4.
Central Venous Catheters
Central venous catheters (CVC), commonly inserted for , are also associated with a risk of . The incidence of CVC-related deep vein () assessed by venography has been reported to vary from 30% to 60% but catheter-related in adult patients is symptomatic in only 5% of cases5.
The wide variability in the incidence of catheter-related may be due to differences in catheter type, position, duration of insertion, type of , and use of different chemotherapeutic agent6.
is also an important risk factor for / in both men and women. Studies have shown that obese individuals have nearly twice the risk of both and 7.
Hormone Replacement Therapy (HRT) and contraceptives
Many women use treatments to alleviate the symptoms of menopause or osteoporosis. These medicines often contain a synthetic version of the hormone called oestrogen, which causes blood to clot more easily. Similarly, birth control methods like the combined contraceptive pill and contraceptive skin patch also contain oestrogen8
If you are already at risk for developing or undergoing treatment, be sure your doctor is aware of any or contraceptive medication you are taking, so you can discuss what is right for you.
Pregnancy can also increase the chances of developing . Pregnant woman can keep their risk at a minimum by watching out for and reducing other risk factors wherever possible. In particular, if you are on bed rest or generally moving slowly, talk with your doctor about types of exercises that can keep your blood flowing.
Other additional risk factors
There are other risk factors, but they are rare and less relevant for cancer patients. For example, some genetic diseases can trigger and these are usually only identified when a patient does not fit the usual profile (recent surgery or cancer). These diseases include rare Protein C, Protein S and Antithrombin III deficiencies.
Interested to know more? Watch our video which explains why the body makes blood clots
If you need more information about any of the above risk factors or conditions, please contact your doctor.
- Hogg K, Carrier M “Prevention and treatment of venous thromboembolism in patients with cancer” Ther Adv Hematol 2011; 3 (1), p. 45-58.
- Blann A, Dunmore S. “Arterial and Venous in Cancer Patients”. Card Res Practice 2011; Article ID 394740.
- Rao B.B., Kalayarasan R, Kate V, Ananthakrishnan “Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management. ISRN Vasc Med 2012*; Article ID 783214.
- Piatek C., O`Connell C.L, Liebman H.A “Treating venous thromboembolism in patients with cancer” Expert Rev Hematol 2012, 5(2), p. 201-209.
- Debordeau P., Chahmi D.K, Zammit C., Farge-Bancel D. “ Venous thromboembolism associated with long-term use of central venous catheters in cancer patients”. Pat Biol 2008; 56 p. 211-219.
- Lee A.Y.Y., Levine M.N., Butler G., Webb C., Constantini L., Gu C., Julian J.A. “Incidence, risk factors and outcomes of catheter-related in adult patients with cancer” J Clin Oncol 2006; 24:p 1404-1408.
- Stein P.D., Beemath A., Olson R.E “ as a risk factor in venous thromboembolism” Am J Med 2005; 118, p. 978-980.
- Moheimani F., Jackson D.E “Venous thromboembolism: classification, risk factors, diagnosis and management. ISRN Hematol 2011, Article ID 124610.